Company intelligence / Profile preview

IPS HEART

Houston, Texas, United Statesipsheart.com ↗

Ownership: Private
Development stage: Phase 1

Overview

IPS HEART has demonstrated strong preclinical efficacy in animal models of heart attack and muscular dystrophies, showing significant improvements in ejection fraction (>50% improvement vs control) and reduction in fibrosis. Their GIVI-MPC program has received Orphan Drug Designation from both the FDA and EMA for DMD/BMD. ISX9-CPC has received multiple Rare Pediatric Disease Designations from the FDA. No human clinical trial results published as of June 2025.

Therapeutic areas: OtherCardiovascularRare Diseases
Modalities: Induced pluripotent stem cell derived therapyStem cell therapySmall moleculemiRNA-based drugRNA therapy
Industry: Biotech

Drug pipeline

3 assets

GIVI-MPC

Preclinical

2 more assets in the full pipeline.

Partnerships

Under formal CDA with large pharmaceutical companies regarding GIVI-MPC partnership opportunities for BMD clinical advancement

Beyond the preview

Go deeper on IPS HEART.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IPS HEART.